US 12,391,706 B2
Multi-target tyrosine kinase inhibitor
Shenglin Luan, Shenzhen (CN); Tian Tang, Shenzhen (CN); Hanmin Huang, Shenzhen (CN); Jing Wu, Shenzhen (CN); Yidong Feng, Shenzhen (CN); Tao Shi, Shenzhen (CN); Hanlin Feng, Shenzhen (CN); and Lin Yu, Shenzhen (CN)
Assigned to SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD., Shenzhen (CN)
Appl. No. 17/795,516
Filed by SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD., Shenzhen (CN)
PCT Filed Feb. 2, 2021, PCT No. PCT/CN2021/074809
§ 371(c)(1), (2) Date Jul. 26, 2022,
PCT Pub. No. WO2021/164538, PCT Pub. Date Aug. 26, 2021.
Claims priority of application No. 202010099747.2 (CN), filed on Feb. 18, 2020.
Prior Publication US 2023/0102146 A1, Mar. 30, 2023
Int. Cl. C07D 495/04 (2006.01); A61K 31/4365 (2006.01); A61P 35/00 (2006.01); C07F 9/6561 (2006.01)
CPC C07D 495/04 (2013.01) [A61K 31/4365 (2013.01); A61P 35/00 (2018.01); C07F 9/6561 (2013.01)] 13 Claims
 
1. A compound or a pharmaceutically acceptable salt, or racemate thereof, wherein the compound has the structure represented by the general formula (I):

OG Complex Work Unit Chemistry
wherein,
R1 is a substituent selected from the group consisting of: carboxyl-substituted C3˜C8 alkyl acyl, substituted or unsubstituted phosphonyl,

OG Complex Work Unit Chemistry
R2 is selected from the group consisting of: hydrogen, halogen, R5-substituted C1˜C8 alkyl and R5-substituted C6˜C12 aryl;
R3, and R4 are independently selected from the group consisting of: hydrogen and R5-substituted C1˜C6 alkyl, or
R3 and R4 constitute a five- to twelve-membered aliphatic heterocycle;
wherein, R5 is selected from the group consisting of: hydrogen, 1˜3 halogens, hydroxyl, C1˜C6 alkoxy and C6˜C12 aryl.